Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Metrics to compare | 4882 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4882PeersSector | |
---|---|---|---|---|
P/E Ratio | −5.8x | −6.4x | −0.6x | |
PEG Ratio | −0.27 | 0.04 | 0.00 | |
Price/Book | 4.0x | 4.9x | 2.6x | |
Price / LTM Sales | 40.7x | 42.9x | 3.3x | |
Upside (Analyst Target) | - | 88.3% | 39.0% | |
Fair Value Upside | Unlock | 21.5% | 4.9% | Unlock |